Tesfaye Biftu

This inventor holds 84 USPTO granted patents and 3 published patent applications, plus 5 CIPO patents and 33 EPO patents, primarily in Diabetes Treatment (CPC class A61K45-06). Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Cytomed, Inc.. Active years: 1985-2025.

USPTO Granted Patents = 84 (Patent Applications = 3)

% Patents Active = 97.6

CIPO Patents = 5 (Patent Applications = 7)

EPO Patents = 33 (Patent Applications = 36)

Average Co-Inventor Count = 3.8

ph-index = 14

Forward Citations = 601(Granted Patents)

Forward Citations (Not Self Cited) = 498(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Old Bridge, NJ (US) (1988)
Parlin, NJ (US) (1990 - 1992)
Belmont, MA (US) (1995 - 2001)
Westfield, NJ (US) (1985 - 2009)
Freehold, NJ (US) (2006 - 2024)

Company Filing History:

45 out of 2,405

Merck Sharp + Dohme Corp.

Merck Shapr & Dohme Corp.

patent

7. 1 out of 36

Merck Sharpe & Dohme Corp.

Millennium Pharmaceuticals Limited

patents

where one patent can have more than one assignee

Years Active: 1985-2025

Loading Chart...

Areas of Expertise:

Dipeptidyl Peptidase-IV Inhibitors

Tricyclic Compounds

Antidiabetic Agents

Thrombin Inhibitors

Aminotetrahydropyrans

Azabenzimidazole Derivatives

Heterocyclic Compounds

Bicyclic Himbacine Derivatives

Cyclic Azabenzimidazole

Crystalline Forms

Biaryl Monobactam Compounds

Chromane Monobactam Compounds

84 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12281114 - NK3 modulators and uses thereof (2025-04-21),

2. D1022708 - Bottle (2024-04-16),

3. 11433055 - Chromane monobactam compounds for the treatment of bacterial infections (2022-09-06),

4. 11230543 - Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections (2022-01-25),

5. 10519115 - Antidiabetic tricyclic compounds (2019-12-31),

6. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),

7. 10399972 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-09-03),

8. 10000454 - Antidiabetic tricyclic compounds (2018-06-19),

9. 9932311 - Antidiabetic tricyclic compounds (2018-04-03),

10. 9868733 - Azabenzimidazole tetrahydrofuran derivatives (2018-01-16),

11. 9556193 - Benzimidazole hexahydrofuro[3,2-b]furan derivatives (2017-01-31),

12. 9540364 - Benzimidazole tetrahydrofuran derivatives (2017-01-10),

13. 9527839 - Benzimidazole tetrahydropyran derivatives (2016-12-27),

14. 9469608 - Thrombin inhibitors (2016-10-18),

15. 9447085 - Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use (2016-09-20),

Title: Innovator Spotlight: Tesfaye Biftu - Pioneering Advances in Antibacterial Compounds

Introduction:

Tesfaye Biftu, a distinguished inventor based in Freehold, NJ, has made significant contributions to the field of pharmaceuticals with his groundbreaking work in developing novel antibacterial compounds. With an impressive portfolio of 82 patents, Biftu's innovations have paved the way for more effective treatments against bacterial infections.

Latest Patents:

Tesfaye Biftu's latest patents include the development of Chromane monobactam compounds and Biaryl monobactam compounds for the treatment of bacterial infections. These compounds show promising potential in combating bacterial strains and offer new solutions in the fight against antibiotic resistance. His dedication to advancing medical science is evident in the formulations and methods he has patented, which hold great promise for improving patient outcomes.

Career Highlights:

Throughout his career, Tesfaye Biftu has garnered experience and expertise from prestigious companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc. His tenure at these renowned pharmaceutical firms has allowed him to work on cutting-edge projects and collaborate with top professionals in the industry. Biftu's innovative spirit and passion for research have driven him to achieve remarkable success in the realm of pharmaceutical inventions.

Collaborations:

In his professional journey, Tesfaye Biftu has had the privilege of collaborating with esteemed colleagues, including Danqing D Feng and Ann E Weber. Together, they have shared insights, expertise, and a common goal of developing pioneering solutions to address the global health challenge of bacterial infections. These collaborations have enriched Biftu's work, fostering a culture of innovation and excellence.

Conclusion:

In conclusion, Tesfaye Biftu stands as a prominent figure in the field of antibacterial research, with a remarkable track record of patenting inventive compounds for treating bacterial infections. His contributions reflect a deep commitment to advancing medical science and improving healthcare outcomes. Biftu's innovative work serves as a testament to the transformative power of scientific ingenuity in addressing pressing global health issues.